Alligator Bioscience AB (FRA:7AL0) ROC %: -79.15% (As of Mar. 2026)

What is Alligator Bioscience AB ROC %?

Alligator Bioscience AB FRA:7AL0 39 ROC % is -79.15% as of Mar. 2026. GuruFocus rates FRA:7AL0 with a GF Score™ of 39/100. The stock has 7 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Alligator Bioscience AB's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -79.15%.

As of today (2026-06-26), Alligator Bioscience AB's WACC % is 43.62%. Alligator Bioscience AB's ROC % is -71.51% (calculated using TTM income statement data). Alligator Bioscience AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Alligator Bioscience AB (FRA:7AL0) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Alligator Bioscience AB's WACC % is 43.62%. Alligator Bioscience AB's ROC % is -71.51% (calculated using TTM income statement data). Alligator Bioscience AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Alligator Bioscience AB ROC % Related Terms

Alligator Bioscience AB ROC % Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB ROC % Chart

Alligator Bioscience AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-206.64

-220.22

-233.11

-110.69

-74.40

Alligator Bioscience AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-95.75	-62.88	-62.72	-87.38	-79.15

39GF Score

Alligator Bioscience AB FRA:7AL0

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Alligator Bioscience AB ROC % Calculation

Alligator Bioscience AB's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-11.18 * ( 1 - 0% )	/	( (19.581	+	10.474)	/ 2 )
=	-11.18	/	15.0275
=	-74.40 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.071	-	0.796	-	( 5.591	-	max(0, 17.513	-	6.207	+	5.591	))
=	19.581

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.164	-	0.561	-	( 5.716	-	max(0, 7.181	-	6.31	+	5.716	))
=	10.474

Alligator Bioscience AB's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-6.628 * ( 1 - 0% )	/	( (10.474	+	6.274)	/ 2 )
=	-6.628	/	8.374
=	-79.15 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.164	-	0.561	-	( 5.716	-	max(0, 7.181	-	6.31	+	5.716	))
=	10.474

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.822	-	0.414	-	( 3.062	-	max(0, 2.819	-	4.953	+	3.062	))
=	6.274

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -79.15% mean?

Alligator Bioscience AB (FRA:7AL0) has a ROC % of -79.15% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Alligator Bioscience AB and its competitors.

Is Alligator Bioscience AB's ROC % too high?

Alligator Bioscience AB's current ROC % is -79.15%. Overall, Alligator Bioscience AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.

How does Alligator Bioscience AB's ROC % compare to VRTX and REGN?

Alligator Bioscience AB's ROC % of -79.15% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current ROC % is -79.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Alligator Bioscience AB stock overvalued right now?

Alligator Bioscience AB (FRA:7AL0) has a current ROC % of -79.15%. The current ROC % is -79.15%. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current ROC % is -79.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:SIMRIS B OSTO:NXTCL XSAT:ABERA OSTO:ELIC NGM:GTAB B OSTO:BIOVIC B OSTO:DMYD B OSTO:IRLAB A OSTO:ALZCUR OSTO:ANNX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ATORX:Sweden 0RK9:UK

Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website https://www.alligatorbioscience.se

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.

39GF Score

Get the complete analysis for FRA:7AL0

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00

Price

View FRA:7AL0 Analysis

See ROC % data for all stocks →